Sarepta Therapeutics, Inc.SRPTNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank71
3Y CAGR-82.2%
5Y CAGR-73.9%
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

3Y CAGR
-82.2%/yr
Annual compound
5Y CAGR
-73.9%/yr
Recent deceleration
Percentile
P71
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
20250.15%
202458.92%
2023-53.99%
202226.59%
2021-512.38%
2020123.54%
2019-17.45%
2018-67.53%
20175.62%
2016-64.47%